Gabapentin in bipolar disorder

A placebo-controlled trial of adjunctive therapy

Atul C. Pande, Jerri G. Crockatt, Carol A. Janney, John L. Werth, Georgia Tsaroucha, L. Altshuler, R. Gerner, C. L. Bowden, L. Rhodes, J. R. Calabrese, M. Shelton, D. L. Dunner, H. Hendrickson, L. Gyulai, R. Hirschfeld, G. B. Kaplan, T. Ketter, R. B. Lydiard, S. L. McElroy, P. E. Keck & 4 others G. Sachs, P. Suppes, J. Zajecka, C. Zarate

Research output: Contribution to journalArticle

278 Citations (Scopus)

Abstract

Objectives: To assess efficacy and safety of gabapentin in the treatment of bipolar disorder. Methods: This was a double-blind, placebo-controlled trial of adjunctive gabapentin (dosed flexibly between 900 and 3600 mg/day). Patients with a lifetime diagnosis of bipolar disorder (type I), and who were currently suffering from symptoms of either mania, hypomania or a mixed state despite ongoing therapy with lithium, valproate, or lithium and valproate in combination were eligible for inclusion. The primary efficacy measures were the baseline to endpoint change in total score on the Young Mania Rating Scale (YMRS) and the Hamilton Depression Rating Scale (HAM-D). Results: Both treatment groups had a decrease in total YMRS from baseline to endpoint, but this decrease was significantly greater in the placebo group (-9) than the gabapentin group (-6) (p < 0.05). No difference between treatments was found for the total score on the HAM-D. Secondary efficacy measures were not different between treatment groups. More patients in the placebo group had changes made to their ongoing lithium therapy (n = 12) compared to the gabapentin group (n = 4). When these patients are removed from the efficacy analysis, the YMRS treatment difference still favors placebo, but is no longer statistically significant. Based on gabapentin plasma levels at termination, some patients did not take the study drug as prescribed. Conclusions: The findings of this study did not demonstrate that gabapentin is an effective adjunctive treatment when administered to outpatients with bipolar disorder.

Original languageEnglish (US)
Pages (from-to)249-255
Number of pages7
JournalBipolar Disorders
Volume2
Issue number3 PART 2
StatePublished - Sep 2000

Fingerprint

Bipolar Disorder
Placebos
Lithium
Valproic Acid
Therapeutics
gabapentin
Outpatients
Depression
Safety
Pharmaceutical Preparations

Keywords

  • Bipolar disorder
  • Clinical trial
  • Gabapentin
  • Mania
  • Placebo-controlled
  • Trial methods

ASJC Scopus subject areas

  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology

Cite this

Pande, A. C., Crockatt, J. G., Janney, C. A., Werth, J. L., Tsaroucha, G., Altshuler, L., ... Zarate, C. (2000). Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Bipolar Disorders, 2(3 PART 2), 249-255.

Gabapentin in bipolar disorder : A placebo-controlled trial of adjunctive therapy. / Pande, Atul C.; Crockatt, Jerri G.; Janney, Carol A.; Werth, John L.; Tsaroucha, Georgia; Altshuler, L.; Gerner, R.; Bowden, C. L.; Rhodes, L.; Calabrese, J. R.; Shelton, M.; Dunner, D. L.; Hendrickson, H.; Gyulai, L.; Hirschfeld, R.; Kaplan, G. B.; Ketter, T.; Lydiard, R. B.; McElroy, S. L.; Keck, P. E.; Sachs, G.; Suppes, P.; Zajecka, J.; Zarate, C.

In: Bipolar Disorders, Vol. 2, No. 3 PART 2, 09.2000, p. 249-255.

Research output: Contribution to journalArticle

Pande, AC, Crockatt, JG, Janney, CA, Werth, JL, Tsaroucha, G, Altshuler, L, Gerner, R, Bowden, CL, Rhodes, L, Calabrese, JR, Shelton, M, Dunner, DL, Hendrickson, H, Gyulai, L, Hirschfeld, R, Kaplan, GB, Ketter, T, Lydiard, RB, McElroy, SL, Keck, PE, Sachs, G, Suppes, P, Zajecka, J & Zarate, C 2000, 'Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy', Bipolar Disorders, vol. 2, no. 3 PART 2, pp. 249-255.
Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G, Altshuler L et al. Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Bipolar Disorders. 2000 Sep;2(3 PART 2):249-255.
Pande, Atul C. ; Crockatt, Jerri G. ; Janney, Carol A. ; Werth, John L. ; Tsaroucha, Georgia ; Altshuler, L. ; Gerner, R. ; Bowden, C. L. ; Rhodes, L. ; Calabrese, J. R. ; Shelton, M. ; Dunner, D. L. ; Hendrickson, H. ; Gyulai, L. ; Hirschfeld, R. ; Kaplan, G. B. ; Ketter, T. ; Lydiard, R. B. ; McElroy, S. L. ; Keck, P. E. ; Sachs, G. ; Suppes, P. ; Zajecka, J. ; Zarate, C. / Gabapentin in bipolar disorder : A placebo-controlled trial of adjunctive therapy. In: Bipolar Disorders. 2000 ; Vol. 2, No. 3 PART 2. pp. 249-255.
@article{fa40b7c9aa7741a8b4628b14e4d11f9e,
title = "Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy",
abstract = "Objectives: To assess efficacy and safety of gabapentin in the treatment of bipolar disorder. Methods: This was a double-blind, placebo-controlled trial of adjunctive gabapentin (dosed flexibly between 900 and 3600 mg/day). Patients with a lifetime diagnosis of bipolar disorder (type I), and who were currently suffering from symptoms of either mania, hypomania or a mixed state despite ongoing therapy with lithium, valproate, or lithium and valproate in combination were eligible for inclusion. The primary efficacy measures were the baseline to endpoint change in total score on the Young Mania Rating Scale (YMRS) and the Hamilton Depression Rating Scale (HAM-D). Results: Both treatment groups had a decrease in total YMRS from baseline to endpoint, but this decrease was significantly greater in the placebo group (-9) than the gabapentin group (-6) (p < 0.05). No difference between treatments was found for the total score on the HAM-D. Secondary efficacy measures were not different between treatment groups. More patients in the placebo group had changes made to their ongoing lithium therapy (n = 12) compared to the gabapentin group (n = 4). When these patients are removed from the efficacy analysis, the YMRS treatment difference still favors placebo, but is no longer statistically significant. Based on gabapentin plasma levels at termination, some patients did not take the study drug as prescribed. Conclusions: The findings of this study did not demonstrate that gabapentin is an effective adjunctive treatment when administered to outpatients with bipolar disorder.",
keywords = "Bipolar disorder, Clinical trial, Gabapentin, Mania, Placebo-controlled, Trial methods",
author = "Pande, {Atul C.} and Crockatt, {Jerri G.} and Janney, {Carol A.} and Werth, {John L.} and Georgia Tsaroucha and L. Altshuler and R. Gerner and Bowden, {C. L.} and L. Rhodes and Calabrese, {J. R.} and M. Shelton and Dunner, {D. L.} and H. Hendrickson and L. Gyulai and R. Hirschfeld and Kaplan, {G. B.} and T. Ketter and Lydiard, {R. B.} and McElroy, {S. L.} and Keck, {P. E.} and G. Sachs and P. Suppes and J. Zajecka and C. Zarate",
year = "2000",
month = "9",
language = "English (US)",
volume = "2",
pages = "249--255",
journal = "Bipolar Disorders",
issn = "1398-5647",
publisher = "Blackwell Munksgaard",
number = "3 PART 2",

}

TY - JOUR

T1 - Gabapentin in bipolar disorder

T2 - A placebo-controlled trial of adjunctive therapy

AU - Pande, Atul C.

AU - Crockatt, Jerri G.

AU - Janney, Carol A.

AU - Werth, John L.

AU - Tsaroucha, Georgia

AU - Altshuler, L.

AU - Gerner, R.

AU - Bowden, C. L.

AU - Rhodes, L.

AU - Calabrese, J. R.

AU - Shelton, M.

AU - Dunner, D. L.

AU - Hendrickson, H.

AU - Gyulai, L.

AU - Hirschfeld, R.

AU - Kaplan, G. B.

AU - Ketter, T.

AU - Lydiard, R. B.

AU - McElroy, S. L.

AU - Keck, P. E.

AU - Sachs, G.

AU - Suppes, P.

AU - Zajecka, J.

AU - Zarate, C.

PY - 2000/9

Y1 - 2000/9

N2 - Objectives: To assess efficacy and safety of gabapentin in the treatment of bipolar disorder. Methods: This was a double-blind, placebo-controlled trial of adjunctive gabapentin (dosed flexibly between 900 and 3600 mg/day). Patients with a lifetime diagnosis of bipolar disorder (type I), and who were currently suffering from symptoms of either mania, hypomania or a mixed state despite ongoing therapy with lithium, valproate, or lithium and valproate in combination were eligible for inclusion. The primary efficacy measures were the baseline to endpoint change in total score on the Young Mania Rating Scale (YMRS) and the Hamilton Depression Rating Scale (HAM-D). Results: Both treatment groups had a decrease in total YMRS from baseline to endpoint, but this decrease was significantly greater in the placebo group (-9) than the gabapentin group (-6) (p < 0.05). No difference between treatments was found for the total score on the HAM-D. Secondary efficacy measures were not different between treatment groups. More patients in the placebo group had changes made to their ongoing lithium therapy (n = 12) compared to the gabapentin group (n = 4). When these patients are removed from the efficacy analysis, the YMRS treatment difference still favors placebo, but is no longer statistically significant. Based on gabapentin plasma levels at termination, some patients did not take the study drug as prescribed. Conclusions: The findings of this study did not demonstrate that gabapentin is an effective adjunctive treatment when administered to outpatients with bipolar disorder.

AB - Objectives: To assess efficacy and safety of gabapentin in the treatment of bipolar disorder. Methods: This was a double-blind, placebo-controlled trial of adjunctive gabapentin (dosed flexibly between 900 and 3600 mg/day). Patients with a lifetime diagnosis of bipolar disorder (type I), and who were currently suffering from symptoms of either mania, hypomania or a mixed state despite ongoing therapy with lithium, valproate, or lithium and valproate in combination were eligible for inclusion. The primary efficacy measures were the baseline to endpoint change in total score on the Young Mania Rating Scale (YMRS) and the Hamilton Depression Rating Scale (HAM-D). Results: Both treatment groups had a decrease in total YMRS from baseline to endpoint, but this decrease was significantly greater in the placebo group (-9) than the gabapentin group (-6) (p < 0.05). No difference between treatments was found for the total score on the HAM-D. Secondary efficacy measures were not different between treatment groups. More patients in the placebo group had changes made to their ongoing lithium therapy (n = 12) compared to the gabapentin group (n = 4). When these patients are removed from the efficacy analysis, the YMRS treatment difference still favors placebo, but is no longer statistically significant. Based on gabapentin plasma levels at termination, some patients did not take the study drug as prescribed. Conclusions: The findings of this study did not demonstrate that gabapentin is an effective adjunctive treatment when administered to outpatients with bipolar disorder.

KW - Bipolar disorder

KW - Clinical trial

KW - Gabapentin

KW - Mania

KW - Placebo-controlled

KW - Trial methods

UR - http://www.scopus.com/inward/record.url?scp=0034278763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034278763&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 249

EP - 255

JO - Bipolar Disorders

JF - Bipolar Disorders

SN - 1398-5647

IS - 3 PART 2

ER -